AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11811645 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy without selective dorsal rhizotomy (PT-only)
Number of subjects: 90
Study 10606875 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg b.w. IVIg (group A)
Number of subjects: 37
Study 10606875 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/kg b.w. IVIg (group B)
Number of subjects: 37
Study 10606875 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g IVIg/kg b.w. (for initial non-responders in group A)
Number of subjects: 37
Study 10606875 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g IVIg/kg b.w. (for initial non-responders in group B)
Number of subjects: 37
Study 10606875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (overall)
Number of subjects: 37
Study 8955434 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0
Study 8955434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1826984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuna (n-3 fatty acids)
Number of subjects: 10
Study 1826984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (n-3 fatty acids)
Number of subjects: 10
Study 7039242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 27
Study 7039242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29939328 — intervention group
Group type: EXPERIMENTAL
Intervention: Framed messages emphasizing contributions of older adults to society
Number of subjects: 767
Study 29939328 — intervention group
Group type: EXPERIMENTAL
Intervention: Framed messages emphasizing aging as a process of accumulating wisdom and energy
Number of subjects: 767
Study 29939328 — intervention group
Group type: EXPERIMENTAL
Intervention: Framed messages discussing mechanisms of prejudice against older adults
Number of subjects: 767
Study 29939328 — intervention group
Group type: COMPARATOR
Intervention: Unframed message about aging
Number of subjects: 767
Study 29939328 — intervention group
Group type: COMPARATOR
Intervention: Control message unrelated to aging
Number of subjects: 767
Study 28158151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625% capsaicin patch (CP)
Number of subjects: 60
Study 28158151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% capsaicin cream
Number of subjects: 60
Study 28158151 — intervention group
Group type: COMPARATOR
Intervention: Repetitive patch application (0.625% CP and 0.075% capsaicin cream)
Number of subjects: 60
Study 25176271 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary preventive ICD implantation
Number of subjects: 33
Study 25176271 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 33
Study 22723570 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 174
Study 22723570 — intervention group
Group type: COMPARATOR
Intervention: escitalopram
Number of subjects: 174
Study 22723570 — intervention group
Group type: COMPARATOR
Intervention: fatigue-free subjects
Number of subjects: 174
Study 21215637 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfortably secured laces
Number of subjects: 20
Study 21215637 — intervention group
Group type: COMPARATOR
Intervention: Loosened laces
Number of subjects: 20
Study 21215637 — intervention group
Group type: EXPERIMENTAL
Intervention: Looser lacing techniques
Number of subjects: 20
Study 18304334 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentor support (two-weekly contact tailored to individual needs)
Number of subjects: 11
Study 18304334 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentor support
Number of subjects: 11
Study 17039655 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 7
Study 17039655 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 7
Study 15369915 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist format
Number of subjects: 32
Study 15369915 — intervention group
Group type: COMPARATOR
Intervention: Global rating form
Number of subjects: 32
Study 10741298 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 40 mg/m2 intravenous push, Docetaxel 75 mg/m2 in 1 h infusion, Cisplatin 75 mg/m2 with pre‐ and posthydration, treatment repeated every 21 days
Number of subjects: 30
Study 9095231 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional immunotherapy with natural pollen extract
Number of subjects: 0
Study 9095231 — intervention group
Group type: EXPERIMENTAL
Intervention: Bet v 1 d isoform
Number of subjects: 0
Study 9095231 — intervention group
Group type: COMPARATOR
Intervention: Naturally occurring pollen Bet v 1 isoforms
Number of subjects: 0
Study 1396370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (80-120 mg)
Number of subjects: 200
Study 1396370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 3907933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 97
Study 3907933 — intervention group
Group type: COMPARATOR
Intervention: Conray 280
Number of subjects: 97
Study 30792050 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural activity program (8 weeks)
Number of subjects: 150
Study 30792050 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 150
Study 29360915 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR decline below cohort median (-1.28 ml/minute/1.73 m2/2 years)
Number of subjects: 20207
Study 29360915 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml/min/1.73 m2/year eGFR decline
Number of subjects: 20207
Study 29360915 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term mortality association
Number of subjects: 20207
Study 27053273 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted NAP SACC UK intervention
Number of subjects: 12
Study 27053273 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 25898077 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promoting programme implemented in treatment schools
Number of subjects: 0
Study 25898077 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promoting programme
Number of subjects: 0
Study 25898077 — intervention group
Group type: COMPARATOR
Intervention: Control group (schools not implementing the programme)
Number of subjects: 0
Study 23672321 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression shirt with the straps fully tensioned (S + T)
Number of subjects: 38
Study 23672321 — intervention group
Group type: COMPARATOR
Intervention: Compression shirt with no strap tension (S)
Number of subjects: 38
Study 20186629 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue perfusion via superior rectal artery
Number of subjects: 20
Study 20186629 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methylene blue perfusion)
Number of subjects: 20
Study 20186629 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue group
Number of subjects: 20
Study 18467721 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-dose temozolomide (TMZ) 75 mg/m²/d for 6 weeks followed by a 2-week rest period
Number of subjects: 49
Study 17062260 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagogastrectomy with wrapping of the pedicled omentum around the esophagogastric anastomosis (Group A)
Number of subjects: 194
Study 17062260 — intervention group
Group type: COMPARATOR
Intervention: Esophagogastrectomy without using the omental graft (Group B)
Number of subjects: 194
Study 12760997 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 36
Study 12760997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 36
Study 11535970 — intervention group
Group type: EXPERIMENTAL
Intervention: Neltenexine (1 sachet thrice daily for 20 days)
Number of subjects: 30
Study 11535970 — intervention group
Group type: COMPARATOR
Intervention: Sobrerol (1 sachet thrice daily for 20 days)
Number of subjects: 30
Study 9489902 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for 1 week
Number of subjects: 160
Study 9489902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 7530124 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound (TRUS)
Number of subjects: 21
Study 7530124 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 21
Study 7530124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7530124 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-induced changes
Number of subjects: 21
Study 3137066 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (1 microgram kg‐1 min‐1)
Number of subjects: 14
Study 3137066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 14
Study 31879996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (measured in pack-years)
Number of subjects: 0
Study 31879996 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed IV analysis method using semiparametric linear transformation models
Number of subjects: 0
Study 29663129 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Cogmed training program (25 sessions, 40 minutes each)
Number of subjects: 0
Study 29663129 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated Cogmed program (25 sessions, 20 minutes each)
Number of subjects: 0
Study 29663129 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study 27973684 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection (sodium hyaluronate)
Number of subjects: 24
Study 27973684 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis with 0.9% NaCl solution (SS)
Number of subjects: 24
Study 26359007 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔBNP% in weaning success group (group C)
Number of subjects: 56
Study 26359007 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔBNP in weaning success group (group C)
Number of subjects: 56
Study 26359007 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis of ΔBNP%
Number of subjects: 56
Study 26359007 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis of ΔBNP
Number of subjects: 56
Study 23829159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) 3 times per week, 20 min per session for 12 weeks
Number of subjects: 38
Study 23829159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 38
Study 23829159 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 21438989 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 3320
Study 21438989 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (96-200 mg/day)
Number of subjects: 3320
Study 19074546 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-based morphometry (VBM) analysis in HD patients
Number of subjects: 22
Study 19074546 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (133 subjects)
Number of subjects: 22
Study 19074546 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (99 subjects)
Number of subjects: 22
Study 19074546 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (66 subjects)
Number of subjects: 22
Study 19074546 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (33 subjects)
Number of subjects: 22
Study 17125496 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate + SP (AS+SP)
Number of subjects: 298
Study 17125496 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate + amodiaquine (AS+AQ)
Number of subjects: 298
Study 17125496 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether + lumefantrine (AL)
Number of subjects: 298
Study 17125496 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AS+SP to AL
Number of subjects: 298
Study 17125496 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AS+AQ to AL
Number of subjects: 298
Study 17125496 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 298
Study 14744844 — intervention group
Group type: EXPERIMENTAL
Intervention: Restless Legs Syndrome (RLS)
Number of subjects: 4310
Study 14744844 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity (number of children)
Number of subjects: 4310
Study 14744844 — intervention group
Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 4310
Study 11703422 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (25 mg t.i.d. for 4 weeks, 50 mg t.i.d. for 12 weeks, 100 mg t.i.d. for 16 weeks)
Number of subjects: 152
Study 11703422 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol combined with metformin
Number of subjects: 152
Study 11703422 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with metformin
Number of subjects: 152
Study 11703422 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol/metformin
Number of subjects: 152
Study 11703422 — intervention group
Group type: COMPARATOR
Intervention: Placebo/metformin
Number of subjects: 152
Study 9206278 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera 2 (three-chip camera)
Number of subjects: 130
Study 9206278 — intervention group
Group type: COMPARATOR
Intervention: Camera 1 (single-chip camera)
Number of subjects: 130
Study 8190572 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine (100 mg/kilo)
Number of subjects: 47
Study 8190572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30459160 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratified treatment approaches in major international cooperative groups
Number of subjects: 0
Study 30459160 — intervention group
Group type: COMPARATOR
Intervention: Current therapies for infant leukemia
Number of subjects: 0
Study 30051222 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist's interventions
Number of subjects: 140
Study 30051222 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist intervention)
Number of subjects: 140
Study 27059833 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercises focusing on pelvic floor muscles (12 weeks)
Number of subjects: 60
Study 27059833 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy modalities and regular exercises (Control)
Number of subjects: 60
Study 25085407 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution
Number of subjects: 187
Study 25085407 — intervention group
Group type: COMPARATOR
Intervention: Control group (distilled water)
Number of subjects: 187
Study 22853847 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/Amlodipine 5 mg (I300/A5)
Number of subjects: 320
Study 22853847 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 300 mg (I300)
Number of subjects: 320
Study 22853847 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 150 mg (I150)
Number of subjects: 320
Study 20929124 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus granule (2.25 g twice a day for two weeks)
Number of subjects: 45
Study 20929124 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for correcting heart failure (including digoxin, diuretics)
Number of subjects: 45
Study 18761785 — intervention group
Group type: EXPERIMENTAL
Intervention: VAL80/HCTZ12.5 mg
Number of subjects: 1175
Study 18761785 — intervention group
Group type: COMPARATOR
Intervention: VAL80 mg
Number of subjects: 1175
Study 15834030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25‐100 mg)
Number of subjects: 217
Study 15834030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 12027831 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic intracranial hypertension (ICH) patients
Number of subjects: 16
Study 12027831 — intervention group
Group type: COMPARATOR
Intervention: Normal data from 16 age‐matched, healthy subjects
Number of subjects: 16
Study 10360500 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-coded Doppler sonography (CCDS)
Number of subjects: 48
Study 10360500 — intervention group
Group type: COMPARATOR
Intervention: Micturating cystography (MC)
Number of subjects: 48
Study 7497559 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine tablets equal to individual average daily caffeine consumption
Number of subjects: 40
Study 7497559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1742450 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive weighted log-rank statistic
Number of subjects: 0
Study 1742450 — intervention group
Group type: COMPARATOR
Intervention: Unweighted log-rank statistic
Number of subjects: 0
Study 7210779 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of diltiazem (D)
Number of subjects: 10
Study 7210779 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of nifedipine (N)
Number of subjects: 10
Study 7210779 — intervention group
Group type: COMPARATOR
Intervention: Comparison between D and N
Number of subjects: 10
Study 30690333 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet use frequency, preferred online activities, Facebook interactions, online risk behaviors (cyberbullying and sexting)
Number of subjects: 58
Study 30690333 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook usage
Number of subjects: 58
Study 30171914 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of receiving chocolate (0%, 50%, 100%)
Number of subjects: 120
Study 30171914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry condition
Number of subjects: 120
Study 30171914 — intervention group
Group type: COMPARATOR
Intervention: Satiated condition
Number of subjects: 120
Study 30171914 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived food addiction (SPFA)
Number of subjects: 120
Study 30171914 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire-to-eat (DtE) chocolate
Number of subjects: 120
Study 26994381 — intervention group
Group type: EXPERIMENTAL
Intervention: LaVita multivitamin and trace element composition
Number of subjects: 0
Study 26994381 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 25407957 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training group (EG)
Number of subjects: 35
Study 25407957 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 35
Study 22146289 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS supplemented with phone interviews
Number of subjects: 133
Study 22146289 — intervention group
Group type: COMPARATOR
Intervention: SMS alone
Number of subjects: 133
Study 21417118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (permanent)
Number of subjects: 24
Study 21417118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (primary)
Number of subjects: 24
Study 21417118 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (permanent)
Number of subjects: 24
Study 21417118 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (primary)
Number of subjects: 24
Study 21417118 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite DSC (permanent)
Number of subjects: 24
Study 21417118 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite DSC (primary)
Number of subjects: 24
Study 17906162 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/E2
Number of subjects: 36
Study 17906162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15652830 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved timolol 0.5%
Number of subjects: 20
Study 15652830 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free timolol 0.5%
Number of subjects: 20
Study 11856083 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mononitrate hydrogel (0.2% isosorbide‐5‐mononitrate), applied twice daily for 3 weeks
Number of subjects: 19
Study 11856083 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel treatment
Number of subjects: 19
Study 11856083 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mononitrate hydrogel
Number of subjects: 19
Study 10667099 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A: 20 MUI of penicillin G per day for 3 weeks, infused over 4 hours
Number of subjects: 16
Study 10667099 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B: 30 MUI of penicillin G per day for 10 days, infused over 6 hours
Number of subjects: 16
Study 7548778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 100 mg tablet
Number of subjects: 11
Study 7548778 — intervention group
Group type: COMPARATOR
Intervention: Cefpodoxime proxetoxil oral solution (2 mg/mL)
Number of subjects: 11
Study 7548778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetoxil oral solution (100 mg) with high-fat meal
Number of subjects: 11
Study 1972140 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.05 microgram/kg/min i.v.)
Number of subjects: 16
Study 475366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 1000 mg
Number of subjects: 12
Study 475366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 1000 mg
Number of subjects: 12
Study 475366 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 9000 1000 mg
Number of subjects: 12
Study 475366 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 1000 mg (empty stomach)
Number of subjects: 12
Study 475366 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 1000 mg (with breakfast)
Number of subjects: 12
Study 475366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 1000 mg (with breakfast)
Number of subjects: 12
Study 30719873 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume multi-use spacer
Number of subjects: 32
Study 30719873 — intervention group
Group type: COMPARATOR
Intervention: Small volume disposable spacer
Number of subjects: 32
Study 30719873 — intervention group
Group type: EXPERIMENTAL
Intervention: Any spacer at 400 µg of salbutamol
Number of subjects: 32
Study 30585458 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zusanli (ST 36) and Neiguan (PC 6), stimulation at 2 Hz for 30 min, twice after surgery at 6-hour intervals.
Number of subjects: 40
Study 30585458 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only (control group).
Number of subjects: 40